BadgerCare Plus and Medicaid SSI ProgramsJanuary 24, 2024
Clinical Criteria updates — September 2023
On September 21, 2023, and October 4, 2023, the Pharmacy and Therapeutic (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Anthem. These policies were developed, revised, or reviewed to support clinical coding edits.
Visit Clinical Criteria to search for specific policies. For questions or additional information, use this email.
Please see the explanation/definition for each category of Clinical Criteria below:
- New: Newly published criteria
- Revised: Addition or removal of medical necessity requirements, new document number
- Updates Marked with an asterisk (*) notate that the criteria may be perceived as more restrictive.
Please share this notice with other providers in your practice and office staff.
Please note:
- The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.
- This notice is meant to inform the provider of new or revised criteria that has been adopted by Anthem only. It does not include details regarding any authorization requirements. Authorization rules are communicated via a separate notice.
Effective date | Clinical Criteria number | Clinical Criteria title | New or revised |
March 1, 2024 | *CC-0248 | Elrexfio (elranatamab-bcmm) | New |
March 1, 2024 | *CC-0249 | Talvey (talquetamab-tgvs) | New |
March 1, 2024 | *CC-0250 | Veopoz (pozelimab-bbfg) | New |
March 1, 2024 | *CC-0251 | Ycanth (cantharidin) | New |
March 1, 2024 | *CC-0018 | Pompe Disease | Revised |
March 1, 2024 | *CC-0021 | Fabrazyme (agalsidase beta) | Revised |
March 1, 2024 | *CC-0046 | Zinplava (bezlotoxumab) | Revised |
March 1, 2024 | CC-0182 | Iron Agents | Revised |
March 1, 2024 | *CC-0068 | Growth Hormones | Revised |
March 1, 2024 | CC-0156 | Reblozyl (luspatercept) | Revised |
March 1, 2024 | *CC-0233 | Rebyota (fecal microbiota, live – jslm) | Revised |
March 1, 2024 | *CC-0020 | Natalizumab Agents (Tysabri, Tyruko) | Revised |
March 1, 2024 | CC-0064 | Interleukin-1 Inhibitors | Revised |
March 1, 2024 | CC-0026 | Testosterone Injectable | Revised |
March 1, 2024 | *CC-0247 | Beyfortus (nirsevimab) | Revised |
Anthem Blue Cross and Blue Shield is the trade name of Compcare Health Services Insurance Corporation. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.
WIBCBS-CD-048722-23-CPN48226
PUBLICATIONS: February 2024 Provider Newsletter
To view this article online:
Or scan this QR code with your phone